Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

The Reputational Dividends of Collaborating with a Highly Reputable Agency: The Case of the FDA and Its Domestic Partner Agencies

Moshe Maor, View ORCID ProfileRaanan Sulitzeanu-Kenan, Meital Balmas
doi: https://doi.org/10.1101/2021.12.01.21267117
Moshe Maor
1Department of Political Science, Hebrew University of Jerusalem, Mount Scopus, Jerusalem 91905, Israel,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: moshe.maor@mail.huji.ac.il Moshe.maor@mail.huji.ac.il
Raanan Sulitzeanu-Kenan
2The Federmann School of Public Policy, The Hebrew University of Jerusalem, Hebrew University of Jerusalem, Mount Scopus, Jerusalem 91905, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Raanan Sulitzeanu-Kenan
  • For correspondence: raanan.s-k@mail.huji.ac.il
Meital Balmas
3Department of Communication and Journalism, The Hebrew University of Jerusalem, Hebrew University of Jerusalem, Mount Scopus, Jerusalem 91905, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: meitalbalmas@gmail.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

What, if any, dividends do agencies reap from collaboration with a highly reputable agency, such as the FDA? Utilizing a dataset covering 30 U.S. federal agencies over a period of 34 years (1980–2013), we estimate the short and long-term reputational effects of interagency collaboration. Collaboration is measured by the number of memorandums of understanding (MOUs) in effect between each agency and the FDA, while agency reputation is assessed using an automated measure of media-coverage valence (positive/negative tone) for each agency-year. To account for potential reverse and reciprocal causality, we utilize cross-lagged fixed-effects models. We find evidence of moderate rises in reputation due to increased collaboration with the FDA. These effects persist significantly for two years, before decaying to null after four years. Employing similar analyses, we furthermore estimate reversed causality – of reputation on the level of consequent collaboration – finding no evidence of such effects.

Research Support Moshe Maor and Raanan Sulitzeanu-Kenan gratefully acknowledge financial support from the Israel Science Foundation under grant 1002/11.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The study was funded by the Israel Science Foundation under grant 1002/11.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced are available online at

https://doi.org/10.7910/DVN/GX6AEU

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted December 07, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
The Reputational Dividends of Collaborating with a Highly Reputable Agency: The Case of the FDA and Its Domestic Partner Agencies
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
The Reputational Dividends of Collaborating with a Highly Reputable Agency: The Case of the FDA and Its Domestic Partner Agencies
Moshe Maor, Raanan Sulitzeanu-Kenan, Meital Balmas
medRxiv 2021.12.01.21267117; doi: https://doi.org/10.1101/2021.12.01.21267117
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
The Reputational Dividends of Collaborating with a Highly Reputable Agency: The Case of the FDA and Its Domestic Partner Agencies
Moshe Maor, Raanan Sulitzeanu-Kenan, Meital Balmas
medRxiv 2021.12.01.21267117; doi: https://doi.org/10.1101/2021.12.01.21267117

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Health Policy
Subject Areas
All Articles
  • Addiction Medicine (161)
  • Allergy and Immunology (414)
  • Anesthesia (90)
  • Cardiovascular Medicine (858)
  • Dentistry and Oral Medicine (159)
  • Dermatology (97)
  • Emergency Medicine (248)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (394)
  • Epidemiology (8561)
  • Forensic Medicine (4)
  • Gastroenterology (383)
  • Genetic and Genomic Medicine (1749)
  • Geriatric Medicine (167)
  • Health Economics (372)
  • Health Informatics (1242)
  • Health Policy (620)
  • Health Systems and Quality Improvement (467)
  • Hematology (196)
  • HIV/AIDS (372)
  • Infectious Diseases (except HIV/AIDS) (10299)
  • Intensive Care and Critical Care Medicine (553)
  • Medical Education (192)
  • Medical Ethics (51)
  • Nephrology (211)
  • Neurology (1677)
  • Nursing (97)
  • Nutrition (251)
  • Obstetrics and Gynecology (326)
  • Occupational and Environmental Health (450)
  • Oncology (928)
  • Ophthalmology (263)
  • Orthopedics (102)
  • Otolaryngology (172)
  • Pain Medicine (113)
  • Palliative Medicine (40)
  • Pathology (253)
  • Pediatrics (534)
  • Pharmacology and Therapeutics (252)
  • Primary Care Research (208)
  • Psychiatry and Clinical Psychology (1768)
  • Public and Global Health (3837)
  • Radiology and Imaging (623)
  • Rehabilitation Medicine and Physical Therapy (320)
  • Respiratory Medicine (520)
  • Rheumatology (208)
  • Sexual and Reproductive Health (167)
  • Sports Medicine (158)
  • Surgery (190)
  • Toxicology (36)
  • Transplantation (101)
  • Urology (76)